CORE--CENTRAL VIRUS CULTURE
核心--中心病毒培养
基本信息
- 批准号:6299622
- 负责人:
- 金额:$ 14.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-03-01 至 2001-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The UAB CFAR has operated a Central Virus Core (CVC) shared resource since
1988. The specific aims of this core are: (1) To provide specially-
designed and centrally-located BSL 2-3 laboratory space to all UAB
investigators so that infectious HIV research can by physically restricted
to specified areas; (2) To provide and maintain the high cost equipment
needed for basic HIV research within the core facility in order to
facilitate and broaden the research capabilities of all investigators and
to avoid redundancy in equipment purchases; (3) To provide ongoing
training, supervision, and monitoring of investigators and their research
staff regarding BSL 2-3 practices required for HIV research with the CVC;
(4) To foster the development of HIV/AIDS research by new and established
investigators by providing a CVC staff with broad experience in basic and
clinical HIV research which is dedicated to these goals. The CVC consists
of two centrally-located biosafety level 2-3 (BSL 2-3) laboratories and
their associated professional and technical staff. These laboratories are
centrally located on the UAB campus in the vicinity of the greatest
concentrations of HIV researchers. Together, they constitute 2500 square
feet of BSL 2-3 laboratory space including nine self-contained 100 square
foot tissue culture suites. Both the individual culture suites and the
outer common equipment areas are completely equipped for molecular,
biological, and clinical HIV research. The core is operated under the
specific usages and priority guidelines established by the Core's Advisory
Committee and complies with NIH/CDC recommendations for safe operating
procedures. Since funded in 1988, the research of 45 principal
investigators with federally funded grants have been accommodated in these
facilities. Currently, the CVC supports the research of 24 UAB faculty
representing 11 different departments and divisions within the School of
Medicine. The CVC has trained, supervised, and assisted 105 researchers
including graduated students, postdoctoral fellows, technicians, and
faculty. Currently, there are a total of 64 active CVC users. In addition
to R01-type projects, the CVC has supporter the research of major NIH
funded program projects and contracts awarded to UAB investigators since
1988, including NCDDG, NCVDG, PEBRA, ACTG, AVEU, NICHD and HIV Genetic
Variation projects. Over 300 peer-reviewed scientific publications have
results from work performed within the CVC since 1993. Funding is
requested to support the basic infrastructure costs of the CVC that remain
despite a substantial chargeback system.
UAB CFAR自2009年以来一直在运行中央病毒核心(CVC)共享资源。
1988.该核心的具体目标是:(1)特别提供-
设计和位于中心的BSL 2-3实验室空间,所有UAB
研究人员,使传染性艾滋病毒的研究,
(2)提供和维护高成本设备
在核心设施内进行艾滋病毒基础研究所需的资金,
促进和扩大所有研究人员的研究能力,
避免重复购买设备;(3)提供持续的
培训、监督和监测研究者及其研究
关于与中心进行艾滋病毒研究所需的BSL 2-3实践的工作人员;
(4)通过新的和建立的艾滋病毒/艾滋病研究,
调查人员提供了一个CVC工作人员与广泛的经验,
致力于这些目标的临床艾滋病毒研究。CVC由
两个位于中心的生物安全2-3级(BSL 2-3)实验室,
其相关专业和技术人员。这些实验室
位于UAB校园的中心,靠近世界上最大的
艾滋病研究人员的聚集地。它们共同构成了2500平方
英尺的BSL 2-3实验室空间,包括9个独立的100平方米
足部组织培养套件。无论是个人文化套房和
外部公共设备区完全配备了分子,
生物学和临床HIV研究。核心是在
核心咨询委员会确定的具体用途和优先准则
符合NIH/CDC的安全操作建议
程序.自1988年资助以来,45名校长的研究
拥有联邦资助赠款的调查人员已被安置在这些
设施目前,CVC支持24 UAB教师的研究
代表11个不同的部门和部门在学校的
药CVC已经培训、监督和协助了105名研究人员
包括研究生、博士后研究员、技术人员,
教师。目前,共有64个活跃的CVC用户。此外
对于R 01型项目,CVC支持主要NIH的研究
自2009年以来,资助的项目和合同授予UAB调查人员,
1988年,包括NCDDG、NCVDG、PEBRA、ACTG、AVEU、NICHD和HIV遗传学
变异项目。超过300篇同行评审的科学出版物
自1993年以来在CVC内进行的工作的结果。资金
要求支持CVC剩余的基本基础设施成本
尽管有大量的退款系统。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN Christopher KAPPES其他文献
JOHN Christopher KAPPES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN Christopher KAPPES', 18)}}的其他基金
The effects of masculinizing gender-affirming hormone therapy for transgender men on susceptibility to HIV-1 infection modelled ex vivo in cervical mucosal tissue
跨性别男性男性化性别肯定激素治疗对子宫颈粘膜组织离体 HIV-1 感染易感性的影响
- 批准号:
10748946 - 财政年份:2023
- 资助金额:
$ 14.28万 - 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
- 批准号:
10553626 - 财政年份:2020
- 资助金额:
$ 14.28万 - 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
- 批准号:
10428455 - 财政年份:2020
- 资助金额:
$ 14.28万 - 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
- 批准号:
9892706 - 财政年份:2020
- 资助金额:
$ 14.28万 - 项目类别:
Analysis of human uterine mucosal cells as targets of HIV-1 infection
人类子宫粘膜细胞作为 HIV-1 感染靶点的分析
- 批准号:
8925576 - 财政年份:2015
- 资助金额:
$ 14.28万 - 项目类别:
Single cycle reporter assay for quantifying HIV-1 Nab
用于量化 HIV-1 Nab 的单循环报告基因检测
- 批准号:
6694007 - 财政年份:2003
- 资助金额:
$ 14.28万 - 项目类别:














{{item.name}}会员




